RHEUMATOID ARTHRITIS: PROBLEMS AND SIGNIFICANCE OF PERSONALIZED MEDICINE


Cite item

Full Text

Abstract

The last decade is prominent for significant progress in research in the field of mechanisms underlying development of rheumatoid arthritis (RA) opening new prospects in pathogenetic treatment of this disease. A great success of RA pharmacotherapy during the last 10 year period is design of novel genetically engineered biological medicines. Achievements of molecular biology, pharmacological genetics and biological information science promote an individual approach to treatment of RA patients within a new conception of individual medicine which considers personal aspects of genomic and proteomic sciences. This novel approach to treatment of RA patients can improve RA outcomes and noticeably reduce cost of the treatment.

About the authors

E L Nasonov

Research Institute of Rheumatology of the Russian Academy of Medical Sciences

Email: sokrat@irramn.ru
д-р мед. наук, проф., акад. РАМН, дир. НИИ ревматологии РАМН

References

  1. Насонов Е. Л., Каратеев Д. Е., Балабанова Р. М. Ревматоидный артрит. В кн.: Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: Изд. группа "ГЭОТАР-Медиа"; 2008. 290—331.
  2. Klareskog L., Cartina A. I, Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659—672.
  3. Alethaha D., Neogi T., Silman A. J. et al. Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthr. and Rheum. 2010; 62: 2569—2581.
  4. Smolen J. S., Aletaha D., Bijsma J.W. J. et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 2010; 69: 631—637.
  5. Насонов Е. Л. (ред.). Ревматология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2010.
  6. Van Vollenhoven R. F. Treatment of rheumatoid arthritis: state of the art 2009. Nat. Rev. Rheumatol. 2009; 5: 531—541.
  7. Насонов Е. Л. Перспективы лечения ревматических заболеваний в начале 21 века. Тер. арх. 2011; 5: 5—9.
  8. Scherer H. U., Dorner T., Burmester G. R. Patient-tailored therapy in rheumatoid arthritis: an editorial review. Curr. Opin. Rheumatol. 2010; 22: 237-245.
  9. Tak P. P. A personalized medicine approach to biological treatment algorithm. Rheumatology 2011.
  10. Emery P., Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann. Rheum. Dis. 2011.
  11. Hughes L. B., Danila M. I., Bridges S. L. Recent advances in personalizing rheumatoid arthritis therapy and management. Personal. Med. 2009; 6: 159-170.
  12. Isaacs J. D., Ferraccioli G. The need for personalized medicine for rheumatoid arthritis. Ann. Rheum. Dis. 2011; 70: 4—7.
  13. Новиков А. А., Александрова Е. Н., Черкасова М. В., Насонов Е. Л. Современные методы лабораторной диагностики ревматоидного артрита. Науч.-практ. ревматол. 2010; 1: 31—45.
  14. Александрова Е. Н., Насонов Е. Л. Современные технологии и перспективы лабораторной диагностики ревматических заболеваний. Тер. арх. 2010; 5: 5—9.
  15. Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann. Rheum. Dis. 2011; 70: 1575—1580.
  16. Lai P., Su Z., Holweg C. T. J. et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit followimg rituximab treatment. Arthr. and Rheum. 2011; 63: 3681—3691.
  17. Sellam J., Hendel-Chavez H., Rouanet S. et al. B cell activation biomarkers as predictive factors for the response to Rituximab in rheumatoid arthritis. A six-month, National, Multicenter, Open-Label Study. Arthr. and Rheum. 2011; 63: 933—938.
  18. Boumans M. J. H., Thurling R. M., Gerlag D. M. et al. Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system. Arthr. and Rheum. 2011; 63: 3187—3194.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies